https://ansm.sante.fr/tableau-acces-derogatoire/tepezza 2025 false false false France French summary of product characteristics guidelines for drug use insurance, health, reimbursement tepezza teprotumumab teprotumumab graves ophthalmopathy graves disease myxedema infusions, intravenous
--- https://www.has-sante.fr/jcms/p_3592956/fr/tepezza-teprotumumab-ophtalmopathie-basedowienne 2025 false false false France evaluation of the transparency committee graves ophthalmopathy tepezza teprotumumab